tradingkey.logo

Carlsmed's preliminary Q4 revenue rises 61% to $15.2 mln

ReutersJan 12, 2026 1:13 PM


Overview

  • Medical tech firm's preliminary Q4 2025 revenue grew 61% yr/yr to $15.2 mln

  • Preliminary full-year 2025 revenue rose 86% to $50.5 mln

  • Company added 101 new surgeon users in 2025, a 61% increase


Outlook

  • Carlsmed anticipates growing recognition and adoption of aprevo in 2026

  • Company focuses on operational excellence for next growth phase in 2026


Result Drivers

  • SURGEON USER BASE - Carlsmed added 101 new surgeon users in 2025, a 61% increase, driving revenue growth

  • APREVO PLATFORM - Increased adoption of aprevo platform technology contributed to Q4 revenue growth


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

$15.20 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Carlsmed Inc is $20.00, about 57.6% above its January 9 closing price of $12.69

Press Release: ID:nGNX9jtcKP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI